Real-world Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
Bristol-Myers Squibb
Summary
The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Aged ≥18 years at index date. * Have a confirmed diagnosis of schizophrenia before index date. * Receipt of an initial prescription order for xanomeline and trospium chloride (XT) and plan to fill and initiate such therapy. * Provide a signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent form (ICF) in accordance with regulatory, local, and institutional guidelines. * Agree to use an electronic device to record, or provide paper entry of, patient-reported outcomes (in English or Spanish). * English or Spani…
Interventions
- Drugxanomeline and trospium chloride (X/T) therapy
According to the product label
Locations (18)
- Local Institution - 0009Orange, California
- Lumos Clinical Research CenterSan Jose, California
- Local Institution - 0003Evanston, Illinois
- Local Institution - 0007Baltimore, Maryland
- Local Institution - 0017Bel Air, Maryland
- Local Institution - 0004Catonsville, Maryland